Quiescent phenotype of tumor-specific CD8+ T cells following immunization

Vladia Monsurrò, Ena Wang, Yoshisha Yamano, Stephen A. Migueles, Monica C. Panelli, Kina Smith, Dirk Nagorsen, Mark Connors, Steven Jacobson, Francesco M. Marincola

Research output: Contribution to journalArticle

73 Citations (Scopus)


In a human melanoma model of tumor antigen (TA)-based immunization, we tested the functional status of TA-specific CD8+ cytotoxic T lymphocytes. A "quiescent" phenotype lacking direct ex vivo cytotoxic and proliferative potential was identified that was further characterized by comparing its transcriptional profile to that of TA-specific T cells sensitized in vitro by exposure to the same TA and the T-cell growth factor interleukin 2 (IL-2). Quiescent circulating tumor-specific CD8+ T cells were deficient in expression of genes associated with T-cell activation, proliferation, and effector function. This quiescent status may explain the observed lack of correlation between the presence of circulating immunization-induced lymphocytes and tumor regression. In addition, the activation of TA-specific T cells by in vitro antigen recall and IL-2 suggests that a complete effector phenotype might be reinstated in vivo to fulfill the potential of anticancer vaccine protocols.

Original languageEnglish
Pages (from-to)1970-1978
Number of pages9
Issue number7
Publication statusPublished - 1 Oct 2004
Externally publishedYes


ASJC Scopus subject areas

  • Hematology

Cite this

Monsurrò, V., Wang, E., Yamano, Y., Migueles, S. A., Panelli, M. C., Smith, K., Nagorsen, D., Connors, M., Jacobson, S., & Marincola, F. M. (2004). Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood, 104(7), 1970-1978. https://doi.org/10.1182/blood-2004-02-0525